Fused deposition modeling 3D printed oral famotidine pulsatile release tablets

The aim of this study was to prepare pulsatile release tablets which provide different drug delayed-release time and realize personalized administration according to the needs of patients.Fused deposition modeling(FDM)3D printing technology was introduced into the field of pharmaceutics in this study,and the feasibility to prepare core-shell pulsatile release tablets was explored by combing 3D printing technology with the traditional manufacturing technology.The core of the pulsatile tablets was a commercial tablet obtained from the traditional technology,and the drug-free shell was prepared by the FDM 3D printing technology.Three kinds of tablet shells were designed using different parameters.Furthermore,the morphology,size,weight,hardness,and in vitro drug release of the 3D printed famotidine pusatile tablets were characterized and evaluated.The results showed that the 3D printed tablets appeared intact without any defects.Different parameters of outer shell affected the size,weight,hardness,and in vitro drug release of the tablets.The tablets achieved a personalized delayed release time varying from 5 to 7 h in vitro.In this way,a new method for preparing pulsatile release tablets and a new way for the personalized administration of pulsatile tablets were explored in this study.

Engineered self-healing single-cavity microcapsules for pulsatile release of drug delivery

A wide range of polymer-based drug delivery systems have been reported for the treatment of variousdiseases.However,the dosing regimen of many drugs,such as stimulator of interferon genes agonists,programmed cell death protein-1 antibodies,and coronavirus disease 2019 vaccines,consists of repeatedintratumoral or intramuscular injections.These repeated administrations may lead to poor adherence,thus resulting in compromised therapeutic outcomes and increased financial burden.Here,we developed a multidose drug delivery platform by engineering polylactic-co-glycolic acid(PLGA)with differentmolecular weights into self-healing single-cavity microcapsules(SSM).This approach showed a flexiblecollocation strategy to achieve customized pulsatile drug release and was fully degradable with goodsafety.Notably,this single-injection delivery system contains only PLGA,holding great promise forclinical translation.

Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices

Dose-dense chemotherapy is the preferred first-line therapy for triple-negative breast cancer(TNBC),a highly aggressive disease with a poor prognosis.This treatment uses the same drug doses as conventional chemotherapy but with shorter dosing intervals,allowing for promising clinical outcomes with intensive treatment.However,the frequent systemic administration used for this treatment results in systemic toxicity and low patient compliance,limiting therapeutic efficacy and clinical benefit.Here,we report local dose-dense chemotherapy to treat TNBC by implanting 3D printed devices with timeprogrammed pulsatile release profiles.The implantable device can control the time between drug releases based on its internal microstructure design,which can be used to control dose density.The device is made of biodegradable materials for clinical convenience and designed for minimally invasive implantation via a trocar.Dose density variation of local chemotherapy using programmable release enhances anti-cancer effects in vitro and in vivo.Under the same dose density conditions,device-based chemotherapy shows a higher anticancer effect and less toxic response than intratumoral injection.We demonstrate local chemotherapy utilizing the implantable device that simulates the drug dose,number of releases,and treatment duration of the dose-dense AC(doxorubicin and cyclophosphamide)regimen preferred for TNBC treatment.Dose density modulation inhibits tumor growth,metastasis,and the expression of drug resistance-related proteins,including p-glycoprotein and breast cancer resistance protein.To the best of our knowledge,local dose-dense chemotherapy has not been reported,and our strategy can be expected to be utilized as a novel alternative to conventional therapies and improve anti-cancer efficiency.

A biomimetic and bioactive scaffold with intelligently pulsatile teriparatide delivery for local and systemic osteoporosis regeneration

Osteoporosis is one of the most disabling consequences of aging,osteoporotic fractures and higher risk of the subsequent fractures leading to substantial disability and deaths,indicating both local fractures healing and the early anti-osteoporosis therapy are of great significance.Teriparatide is strong bone formation promoter effective in treating osteoporosis,while side effects limit clinical applications.Traditional drug delivery is lack of sensitive and short-term release,finding a new non-invasive and easily controllable drug delivery to not only repair the local fractures but also improve total bone mass has remained a great challenge.Thus,bioinspired by the natural bone components,we develop appropriate interactions between inorganic biological scaffolds and organic drug molecules,achieving both loaded with the teriparatide in the scaffold and capable of releasing on demand.Herein,biomimetic bone microstructure of mesoporous bioglass,a near-infrared ray triggered switch,thermosensitive liposomes based on a valve,and polydopamine coated as a heater is developed rationally for osteoporotic bone regeneration.Teriparatide is pulsatile released from intelligent delivery,not only rejuvenating osteoporotic bone defect,but also presenting strong systemic anti-osteoporosis therapy.This biomimetic bone carrying novel drug delivery platform is well worth expecting to be a new promising strategy and clinically commercialized to help patients survive from the osteoporotic fracture.